Advertisement

Complement Detection in Human Tumors by Immunohistochemistry and Immunofluorescence

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2227)

Abstract

Tumors contain a complement rich microenvironment in which all cell types (e.g., tumor cells and stromal cells) are able to produce different proteins. We developed immunohistochemistry (IHC) assays allowing to identify on paraffin embedded tumor sections, not only the complement producing cells but also the complement activation fragments which result from activation of complement cascade within the tumor. The local production of complement can be detected by cytoplasmic staining, whereas the activation fragments are localized at the surface of the cells. There is a high heterogeneity of the staining within tumors but also between patients. Semi-quantification of the staining in large cohorts of patients allows to investigate the prognostic impact of the local complement production and activation. Here we explain the staining process for C1q, C4, and C3 in human paraffin-embedded tumor sections by immunofluorescence and immunohistochemistry.

Key words

Complement Immunohistochemistry (IHC) Immunofluorescence (IF) Tumors Production Activation Prognostic 

Notes

Acknowledgments

This work was supported by a grant from Association pour la Recherche sur le Cancer (ARC); Cancer Research for Personalized Medicine (CARPEM) (to LTR) and La Ligue contre le cancer (RS19/75-111 to LTR). This work was also supported by INSERM, University Paris Descartes, Sorbonne University, CARPEM, and the Labex Immuno-Oncology Excellence Program. MVD received a PhD fellowship from ARC.

References

  1. 1.
    Roumenina L, Daugan MV, Petitprez F, Sautès-Fridman C, Fridman WH (2019) Context-dependent roles of complement in cancer. Nat Rev Cancer 19(12):698–715CrossRefGoogle Scholar
  2. 2.
    Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT (2015) Complement system part II: role in immunity. Front Immunol 6:257PubMedPubMedCentralGoogle Scholar
  3. 3.
    Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD (2018) Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 18:5–18CrossRefGoogle Scholar
  4. 4.
    Ajona D et al (2013) Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst 105:1385–1393CrossRefGoogle Scholar
  5. 5.
    Roumenina LT et al (2019) Tumor cells hijack macrophage-produced complement C1q to promote tumor growth. Cancer Immunol Res 7:1091–1105.  https://doi.org/10.1158/2326-6066.CIR-18-0891CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2021

Authors and Affiliations

  1. 1.INSERM, UMR_S 1138, Inflammation, Complement and Cancer Team, Centre de Recherche des Cordeliers, Sorbonne UniversitésUniversité de ParisParisFrance

Personalised recommendations